Companion Animal Pet Markets

1
(No Transcript)
2

• Companion Animal (Pet) Markets
• USA (65-70 million dogs/ 70 million cats)
• UK (6.5 million dogs/7.5 million cats)
• Europe (30-50 million dogs)
• Japan (11 million dogs/8 million cats)
• Newly emerging markets
• China (22 million)
• Brazil (30 million)

3

• Will owners spend on their pets? (USA)
• Market growing by 6 yearly (recession free)
• 65 more spending by Americans since 2000
• 18,000 Ralph Lauren pet carriers
• 40 billion spent by US owners in 2006

4

• Healthcare spending (USA)
• 18 billion spent on healthcare
• 9 billion pharmaceuticals
• 4.5 billion diagnostics
• 4.5 billion veterinary treatments

5

• Healthcare spending (USA)
• Spending on the health of pets now includes
• Chemotherapy
• Organ transplants
• Stem cell transplants (45,000 per transplant)
• Pets are receiving quality healthcare equal to
  human standards

6

• Why do owners spend?
• Pets are integral members of the family
• Emotional bond
• Surrogate children
• Owners spend more on pets healthcare than own

7

• Benefits to human healthcare sector
• Dogs exhibit similar diseases to humans
• Cancer
• Renal
• Cardiac
• Canine genome sequenced (rapid ID of SNPs)
• Over 250 breeds each with idiosyncrasies for
  particular disease(s)
• NCI Canine Comparative Oncology Genomics
  Consortium
• Tissue bank
• Drug development

8

• Important diseases
• Cancer (1 in 4 dogs)
• Renal
• Arthritis (10 million dogs)
• Cardiac

9

• PetScreen
• Founded by two entrepreneurs (January 2004)
• Privately owned
• Activities funded by
• private finance
• debt
• grant (e.g. UKTi Passport 2 Export/SOLO
  awards/GRD)

10
Objectives

• Develop diagnostic assays with application for
• Biomarkers for disease detection
• Biomarkers for disease progression
• Therapy selection
• Areas of commercial interest
• Cancer
• Renal
• Osteoarthritis

11
Research and Development

• Private Finance
• 2 x DTI Grant for Research and Development (75K)
• DTI Development grant (DTI grant 190K)
• EPSRC CASE PhD studentship (bioinformatics)
• Collaborative agreements with US vets in practice
  (stem cell transplant studies)

12

• Management
• Executive Team
• CEO Dr. Kevin Slater
• Chairman Mr. Graeme Radcliffe
• Technical Director Dr. Shahid Mian
• Non-Executive team
• Dr. Graeme Blackwood
• Dr. John Whitehead
• Mr. Charles Gregson

13

• Strengths in Innovation
• Released first commercial veterinary proteomic
  assay for canine lymphoma using chilled
  transportation
• Issuance of patents for lymphoma biomarkers
• Developing biomarker assays for
• Osteosarcoma
• Haemangiosarcoma
• Mast cell tumours
• Renal (DTI assisted)

14

• Milestones to date
• DC assay (ex-vivo cell based drug reporter assay)
  launched 2005
• Lymphoma proteomic biomarker assay launched
  November 2006
• 550 UK vets marketing products
• 200 US vets marketing products

15

• Milestones to date
• Distribution agreement with NWL
• Global logistics deal with FedEx
• Collaborative deals with major US veterinary
  diagnostic companies to develop new screens
• approx 1000 hospitals as route to market

16

• Milestones to date
• Research contract with a top 5 global
  pharmaceutical company for biomarker discovery
  programmes
• Negotiating with veterinary diagnostic companies
  in
• Taiwan
• Japan
• France

17

• Future
• Estimated UK oncology sales of 4M by 2009 (UK)
• Development of additional assays e.g. CRD
• Estimates from US partners at 50,000 assays (2M)
• Increase staff within next 12 months
• sales staff by 5
• laboratory by 2
• Identifying VC to establish US operation

18

Four legs
Four legs
to
to
Two legs
Two legs
19

• Parting thought
• They say the dog is mans best friend. I dont
  believe that. How many of your friends have you
  neutered?
• Larry Reeb